The immunomodulatory effect of the antidepressant sertraline in an experimental autoimmune encephalomyelitis mouse model of multiple sclerosis

NeuroImmunoModulation

Volumn 18, Issue 2, 2010, Pages 117-122

  Taler, Michal ^a   Gil Ad, Irit ^a   Korob, Inna ^a   Weizman, Abraham ^a,b  

^a TEL AVIV UNIVERSITY   (Israel)

^b GEHA MENTAL HEALTH CENTER   (Israel)

Author keywords

Cytokines; Experimental autoimmune encephalomyelitis; Immune system; Multiple sclerosis; Sertraline

Indexed keywords

DEXAMETHASONE; GAMMA INTERFERON; INTERLEUKIN 2; PAROXETINE; SERTRALINE; TUMOR NECROSIS FACTOR ALPHA;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG EFFECT; EX VIVO STUDY; FEMALE; IMMUNOMODULATION; MOUSE; MULTIPLE SCLEROSIS; NONHUMAN; PRIORITY JOURNAL; SPLEEN CELL; WEIGHT REDUCTION;

ANIMALS; ANTIDEPRESSIVE AGENTS; CELL SURVIVAL; CYTOKINES; DISEASE MODELS, ANIMAL; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; FEMALE; IMMUNOLOGIC FACTORS; LYMPHOCYTES; MICE; MICE, INBRED C57BL; MULTIPLE SCLEROSIS; SEROTONIN UPTAKE INHIBITORS; SERTRALINE;

EID: 78349244486     PISSN: 10217401     EISSN: None     Source Type: Journal    
DOI: 10.1159/000321634     Document Type: Article

References (31)

1. Fong JS, Rae-Grant A, Huang D: Neurodegeneration and neuroprotective agents in multiple sclerosis. Recent Pat CNS Drug Discov 2008;3:153-165.
2. Miller RH, Mi S: Dissecting demyelination. Nat Neurosci 2007;10:1351-1354.
3. Weiner HL: A shift from adaptive to innate immunity: a potential mechanism of disease progression in multiple sclerosis. J Neurol 2008;255:3-11.
4. Gold R, Linington C, Lassmann H: Understanding pathogenesis and therapy of multiple sclerosis via animal models: 70 years of merits and culprits in experimental autoimmune encephalomyelitis research. Brain 2006;129:1953-1971.
5. Swanborg RH: Experimental autoimmune encephalomyelitis in the rat: lessons in T-cell immunology and autoreactivity. Immunol Rev 2001;184:129-135.
6. Anderson GM, Benett AJ, Weld KP, Pushas JG, Ocame DM, Higley JD: Serotonin in cisternal cerebrospinal fluid of rhesus monkeys: basal levels and effects of sertraline administration. Psychopharmacology (Berl) 2002;161:95-99.
7. Taler M, Gil-Ad I, Lomnitski L, Korov I, Baharav E, Bar M, Zolokov A, Weizman A: Immunomodulatory effect of selective serotonin reuptake inhibitors (SSRIs) on human T lymphocyte function and gene expression. Eur Neuropsychopharmacol 2007;17:774-780.
8. Serafeim A, Holder MJ, Grafton G, Chamba A, Drayson MT, Luong QT, Bunce CM, Gregory CD, Barnes NM, Gordon J: Selective serotonin reuptake inhibitors directly signal for apoptosis in biopsy-like Burkitt lymphoma cells. Blood 2003;15:101:3212-3219.
9. Leonard BE: The immune system, depression and the action of antidepressants. Prog Neuropsychopharmacol Biol Psychiatry 2001;25:767-780.
10. Taler M, Bar M, Korob I, Lomnitski L, Baharav E, Grunbaum-Novak N, Weizman A, Gil-Ad I: Evidence for an inhibitory immunomodulatory effect of selected antidepressants on rat splenocytes: possible relevance to depression and hyperactive-immune disorders. Int Immunopharmacol 2008;8:526-533.
11. Hayman-Amit B, Gil-Ad I, Taler M, Bar M, Zolokov A, Weizman A: Proapoptotic and chemosensitizing effects of selective serotonin reuptake inhibitors on T cell lymphoma/leukemia (Jurkat) in vitro. Eur Neuropsychopharmacol 2009;19:726-734.
12. Abdel-Salam OM, Nofal SM, El-Shenawy SM: Evaluation of the anti-inflammatory and anti-nociceptive effects of different antidepressants in the rat. Pharmacol Res 2003;48:157-165.
13. Ehde DM, Bombardier CH: Depression in persons with multiple sclerosis. Phys Med Rehabil Clin N Am 2005;16:437-448.
14. Kessing LV, Harhoff M, Andersen PK: Increased rate of treatment with antidepressants in patients with multiple sclerosis. Int Clin Psychopharmacol 2008;23:54-59.
15. Stromnes IM, Goverman JM: Active induction of experimental allergic encephalomyelitis. Nat Protoc 2006;1:1810-1819.
16. Gilgun-Sherki Y, Panet H, Melamed E, Offen D: Riluzole suppresses experimental autoimmune encephalomyelitis: implications for the treatment of multiple sclerosis. Brain Res 2003;989:196-204.
17. Mendel I, Katz A, Kozak N, Ben-Nun A, Revel M: Interleukin-6 functions in autoimmune encephalomyelitis: a study in genetargeted mice. Eur J Immunol 1998;28:1727-1737.
18. 3H] thymidine incorporation assay. J Immunol Methods 1994;170:211-224.
19. Begolka WS, Miller SD: Cytokines as intrinsic and exogenous regulators of pathogenesis in experimental autoimmune encephalomyelitis. Res Immunol 1998;149:771-781.
20. Hafler DA: Multiple sclerosis. J Clin Invest 2004;113:788-794.
21. Steinman, L: Multiple sclerosis: a two-stage disease. Nat Immunol 2001;2:762-764.
22. Minden SL, Schiffer RB: Affective disorders in multiple sclerosis: review and recommendations for clinical research. Arch Neurol 1990;47:98-104.
23. Raison CL, Capuron L, Miller AH: Cytokines sing the blues: inflammation and the pathogenesis of depression. Trends Immunol 2006;27:24-31.
24. Anisman H, Merali Z, Poulter MO, Hayley S: Cytokines as a precipitant of depressive illness: animal and human studies. Curr Pharm Des 2005;11:963-972.
25. Smith RS: The macrophage theory of depression. Med Hypotheses 1991;35:298-306.
26. Cloonan SM, Drozgowska A, Fayne D, Williams DC: The antidepressants maprotiline and fluoxetine have potent selective antiproliferative effects against Burkitt lymphoma independently of the norepinephrine and serotonin transporters. Leukemia Lymphoma 2010;51:523-539.
27. Vollmar P, Nessler S, Kalluri SR, Hartung HP, Hemmer B: The antidepressant venlafaxine ameliorates murine experimental autoimmune encephalomyelitis by suppression of pro-inflammatory cytokines. Int J Neuropsychopharmacol 2009;12:525-536.
28. Weinstock-Guttman B, Ransohoff R, Kinkel R, Kinkel R: The interferons: biological effects, mechanisms of action, and use in multiple sclerosis. Ann Neurol 1995;37:7-15.
29. Mohr DC, Goodkin DE, Islar J, Hauser SL, Genain CP: Treatment of depression is associated with suppression of nonspecific and antigen-specific T (H) 1 responses in multiple sclerosis. Arch Neurol 2001;58:1081-1086.
30. Clanet MG, Brassat D: The management of multiple sclerosis patients. Curr Opin Neurol 2000;13:263-270.
31. Noseworthy, JH, Lucchinetti C, Rodriguez M, Weinshenker BG: Multiple sclerosis. N Eng J Med 2000;34:3938-3952.